CA2651726C - Use of combination preparations, comprising antimycotics - Google Patents

Use of combination preparations, comprising antimycotics Download PDF

Info

Publication number
CA2651726C
CA2651726C CA2651726A CA2651726A CA2651726C CA 2651726 C CA2651726 C CA 2651726C CA 2651726 A CA2651726 A CA 2651726A CA 2651726 A CA2651726 A CA 2651726A CA 2651726 C CA2651726 C CA 2651726C
Authority
CA
Canada
Prior art keywords
use according
therapy
candida
thrush
adhesion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2651726A
Other languages
English (en)
French (fr)
Other versions
CA2651726A1 (en
Inventor
Christian Noe
Marion Noe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2651726A1 publication Critical patent/CA2651726A1/en
Application granted granted Critical
Publication of CA2651726C publication Critical patent/CA2651726C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA2651726A 2006-05-12 2007-05-10 Use of combination preparations, comprising antimycotics Active CA2651726C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ATA826/2006 2006-05-12
AT8262006 2006-05-12
PCT/AT2007/000227 WO2007131253A2 (de) 2006-05-12 2007-05-10 Verwendung von kombinationspräparaten, umfassend antimykotika

Publications (2)

Publication Number Publication Date
CA2651726A1 CA2651726A1 (en) 2007-11-22
CA2651726C true CA2651726C (en) 2015-12-15

Family

ID=37903545

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2651726A Active CA2651726C (en) 2006-05-12 2007-05-10 Use of combination preparations, comprising antimycotics

Country Status (19)

Country Link
US (2) US8552042B2 (https=)
EP (2) EP2018164B1 (https=)
JP (1) JP2009536926A (https=)
CN (1) CN101484162A (https=)
AU (1) AU2007250502B2 (https=)
CA (1) CA2651726C (https=)
CY (1) CY1119094T1 (https=)
DK (1) DK2018164T3 (https=)
ES (1) ES2627268T3 (https=)
HR (1) HRP20170793T1 (https=)
HU (1) HUE033499T2 (https=)
LT (1) LT2018164T (https=)
NO (2) NO342103B1 (https=)
PL (1) PL2018164T3 (https=)
PT (1) PT2018164T (https=)
RS (1) RS56044B1 (https=)
RU (1) RU2008148977A (https=)
SI (1) SI2018164T1 (https=)
WO (1) WO2007131253A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI23311A (sl) * 2010-03-19 2011-09-30 Kemijski inštitut Farmacevtska kombinacija acetilsalicilne kisline in protiglivne substance za uničevanje ali inhibicijo rasti in replikacije gliv
CN102210649A (zh) * 2010-04-09 2011-10-12 上海医药科技发展有限公司 一种两性霉素b乳膏及其制备方法
FR2993179B1 (fr) * 2012-07-13 2016-01-08 Lesaffre & Cie Levure saccharomyces cerevisiae pour prevenir et/ou traiter les mycoses vaginales
CN103044408A (zh) * 2013-01-21 2013-04-17 万礼 在治疗恶性肿瘤时应用的伊曲康唑或其盐及其组合物
US8883747B1 (en) * 2013-10-09 2014-11-11 Craig W. Carver Topical antifungal compositions and methods of use thereof
BR112017014295B1 (pt) 2015-01-13 2023-04-25 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A Composição farmacêutica.
CN104920360B (zh) * 2015-06-18 2017-04-12 青岛农业大学 丁苯羟酸在制备用于防治由植物病原菌引起的植物病害的杀菌剂中的用途
EP3482744A1 (de) 2017-11-14 2019-05-15 ProFem GmbH Emulsionen zur topischen behandlung urogenitaler und dermaler infektionen
BR112020009454A2 (pt) 2017-11-14 2020-10-13 Profem Gmbh emulsões para o tratamento de infecções da mucosa
EP3482743A1 (de) 2017-11-14 2019-05-15 ProFem GmbH Emulsionen zur behandlung von scheideninfektionen
FR3089788B1 (fr) * 2018-12-17 2020-12-18 Lesaffre & Cie Souche de levure Saccharomyces cerevisiae pour le traitement et/ou la prévention de candidoses oropharyngées
US20250302821A1 (en) * 2022-05-12 2025-10-02 St. Jude Children's Research Hospital, Inc. Synergistic antifungal composition and method
WO2024187210A1 (de) 2023-03-15 2024-09-19 Profem Gmbh Kombinationsarzneimittel zur behandlung und reduktion der rückfallraten vaginaler mykosen

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6471823A (en) * 1987-09-12 1989-03-16 Rohto Pharma Sustained remedy for vaginal candidiasis
US5087620A (en) * 1990-05-17 1992-02-11 Bristol-Myers Squibb Co. Controlled dermal penetration enhancement using imidazoles
ES2079994B1 (es) * 1992-10-07 1996-08-01 Cusi Lab Formulacion farmaceutica a base de polimixina-trimetoprim y un agente antiinflamatorio para su utilizacion topica oftalmica y otica.
EP0735861A1 (en) * 1993-12-23 1996-10-09 The Procter & Gamble Company Tissue moisturizing and antimicrobial compositions
US6416779B1 (en) * 1997-06-11 2002-07-09 Umd, Inc. Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections
US6159977A (en) 1998-11-16 2000-12-12 Astan, Inc. Therapeutic anti-fungal nail preparation
WO2000048633A1 (en) 1999-02-19 2000-08-24 Ligocyte Pharmaceuticals, Inc. Antibodies against hydrophobic proteins that are protective against candidiasis
EP1191939B1 (en) * 1999-03-24 2007-10-17 Zengen, Inc. Antimicrobial amino acid sequences derived from alpha-melanocyte-stimulating hormone
GB0108082D0 (en) 2001-03-30 2001-05-23 Novartis Consumer Health Sa Topical composition
US20030181384A1 (en) * 2001-09-06 2003-09-25 Podolsky Daniel K. Methods and compositions for treating vaginal, cervical, and uterine epithelial lesions
US20040142910A1 (en) * 2002-10-21 2004-07-22 Aegis Biosciences Llc Sulfonated styrene copolymers for medical uses
WO2004060283A2 (en) * 2002-12-16 2004-07-22 Nitromed, Inc. Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
JPWO2005000287A1 (ja) 2003-06-25 2006-10-05 久光製薬株式会社 水虫治療用外用剤
ES2237298B1 (es) 2003-07-16 2006-11-01 Italfarmaco, S.A. Formulaciones mucoadhesivas semisolidas.
WO2005009342A2 (en) * 2003-07-16 2005-02-03 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
TWI290051B (en) 2004-05-28 2007-11-21 Schering Corp Particulate-stabilized injectable pharmaceutical compositions of Posaconazole

Also Published As

Publication number Publication date
EP3192507B1 (de) 2020-07-08
CA2651726A1 (en) 2007-11-22
RS56044B1 (sr) 2017-09-29
HUE033499T2 (en) 2017-12-28
SI2018164T1 (sl) 2017-07-31
US20090208558A1 (en) 2009-08-20
JP2009536926A (ja) 2009-10-22
WO2007131253A2 (de) 2007-11-22
RU2008148977A (ru) 2010-06-20
AU2007250502B2 (en) 2013-11-28
AU2007250502A1 (en) 2007-11-22
DK2018164T3 (en) 2017-06-12
US8815925B2 (en) 2014-08-26
NO20085181L (no) 2009-02-10
PL2018164T3 (pl) 2017-08-31
CN101484162A (zh) 2009-07-15
CY1119094T1 (el) 2018-01-10
LT2018164T (lt) 2017-07-10
EP3192507A1 (de) 2017-07-19
ES2627268T3 (es) 2017-07-27
EP2018164A2 (de) 2009-01-28
NO20180083A1 (no) 2009-02-10
PT2018164T (pt) 2017-06-12
NO342103B1 (no) 2018-03-26
HRP20170793T1 (hr) 2017-10-06
NO345064B1 (no) 2020-09-14
EP2018164B1 (de) 2017-03-01
WO2007131253A3 (de) 2008-11-27
US8552042B2 (en) 2013-10-08
US20140030312A1 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
CA2651726C (en) Use of combination preparations, comprising antimycotics
ES2879550T3 (es) Inhibidores de epn para tratar enfermedades caracterizadas por la dilatación o remodelación auriculares.
AU2010212634B2 (en) Combination of avermectins or mylbemycins with adrenergic receptors for treating or preventing skin diseases
US20030017207A1 (en) Compositions and methods for treating vulvovaginitis and vaginosis
AU2017261517B2 (en) Use of combination preparations, comprising antimycotics
MD4802C1 (ro) Utilizarea derivatului de glutaramidă pentru tratarea afecţiunilor, asociate cu activitatea aberantă a citokinelor
US20150164837A1 (en) Use of amphoteric surfactants for the prevention and treatment of pathogenic vaginal biofilms in vaginal infections
JP2019510761A (ja) 膣真菌感染症の治療のためのグルコノデルタ−ラクトン
RU2293558C2 (ru) Средство для лечения гинекологических и проктологических заболеваний
AU2013254945A1 (en) Use of combination preparations, comprising antimycotics
US20110195987A1 (en) Treatment with cholinergic agonists
JP2007518797A (ja) 膣感染症の処置のための、フルコナゾール−チニダゾールの組み合わせ、ならびに、その組成物、調製プロセスおよび使用
IT202300010005A1 (it) Rutina per il trattamento dell’epidermolisi bollosa
AU2024320936A1 (en) Compositions for use in the treatment of bacterial vaginosis
OLTEAN MANAGEMENT OF MUCOCUTANEOUS CANDIDIASIS
AU2002309593A1 (en) Composition comprising antifungal agents for treating vulvovaginitis and vaginosis
MXPA06008279A (en) Fluconazole-tinidazole combination for the treatment of vaginal infections, composition thereof and preparation and use of same

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD

Year of fee payment: 17

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241106

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241106

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241106

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251029

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251110

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 18TH ANNIV.) - STANDARD

Year of fee payment: 18

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251114

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251114

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260224